PRESS RELEASE: Pittsburgh, United States – December 15, 2025 – SNS Research Publishes Comprehensive 2025–2035 Global Dermatological Drugs Market Report
Pittsburgh, PA — 12/15/2025 - SNS Research Group has published its flagship report, “Dermatological Drugs Market: 2025–2035 – Opportunities, Challenges, Strategies & Forecasts,” delivering a comprehensive, data-driven assessment of the global dermatological therapeutics market.
The report positions dermatological drugs as the largest and most strategically important segment within the broader dermatology market, with global spending projected to reach $52.8 billion by 2025. Growth is driven by rising prevalence of chronic inflammatory skin diseases, persistent unmet medical need, and rapid innovation across biologics, targeted oral therapies, advanced topicals, and next-generation delivery technologies.
The analysis captures a market undergoing structural transformation. Advanced biologics now represent the primary growth engine, redefining standards of care in psoriasis, atopic dermatitis, alopecia areata, and other immune-mediated skin disorders. IL-23 and IL-17 inhibitors are setting new benchmarks for long-term disease control, while TYK2 inhibitors are reshaping competition by combining targeted efficacy with oral convenience. Parallel innovation in topical therapies—including JAK and PDE4 inhibitors—is expanding treatment optionality and improving patient adherence.
The report provides full market sizing and forecasts from 2025 to 2035, segmented across:
Beyond quantitative forecasts, the report delivers deep coverage of:
The findings highlight intensifying competitive pressure driven by biosimilars, particularly following the 2025 entry of multiple ustekinumab biosimilars, forcing originators to deploy aggressive lifecycle, pricing, and access strategies. Strategic acquisitions and alliances continue to reshape the landscape, reinforcing a broad industry pivot toward precision immunology and differentiated mechanisms.
The full "Dermatological Drugs 2025 Market" report, is available at: https://www.snsresearch.com/dermatological-drugs-market.html
The report is designed for pharmaceutical executives, strategy and business development teams, investors, and policymakers requiring high-fidelity market intelligence to support decision-making in dermatology.
An accompanying Excel data suite provides all underlying quantitative forecasts and a 2025 clinical pipeline dataset, enabling direct integration into internal models and strategy workflows.
About SNS Research Group LLC
SNS Research Group LLC is a B2B healthcare and pharmaceutical intelligence firm delivering high-signal market reports, clinical pipeline datasets, and executive-grade analysis across specialty therapeutics. The firm focuses on markets where biology, competition, and commercial strategy intersect.
Contact:
SNS Research Group
www.snsresearch.com
[email protected]
The report positions dermatological drugs as the largest and most strategically important segment within the broader dermatology market, with global spending projected to reach $52.8 billion by 2025. Growth is driven by rising prevalence of chronic inflammatory skin diseases, persistent unmet medical need, and rapid innovation across biologics, targeted oral therapies, advanced topicals, and next-generation delivery technologies.
The analysis captures a market undergoing structural transformation. Advanced biologics now represent the primary growth engine, redefining standards of care in psoriasis, atopic dermatitis, alopecia areata, and other immune-mediated skin disorders. IL-23 and IL-17 inhibitors are setting new benchmarks for long-term disease control, while TYK2 inhibitors are reshaping competition by combining targeted efficacy with oral convenience. Parallel innovation in topical therapies—including JAK and PDE4 inhibitors—is expanding treatment optionality and improving patient adherence.
The report provides full market sizing and forecasts from 2025 to 2035, segmented across:
- Seven therapeutic categories
- Three routes of administration
- OTC versus prescription drugs
- Four distribution channels
- Three major drug classes, including biologics, small molecules, and gene & emerging therapies
- Twenty-six country markets across five global regions
Beyond quantitative forecasts, the report delivers deep coverage of:
- Dermatological disorders and application areas
- Drug delivery technologies and formulation innovation
- Competitive dynamics, including patent expirations and biosimilar entry
- Late-stage and emerging clinical pipeline trends
- Industry roadmap, value chain structure, and ecosystem evolution
- Profiles and strategies of 83 leading dermatology and biopharmaceutical companies
The findings highlight intensifying competitive pressure driven by biosimilars, particularly following the 2025 entry of multiple ustekinumab biosimilars, forcing originators to deploy aggressive lifecycle, pricing, and access strategies. Strategic acquisitions and alliances continue to reshape the landscape, reinforcing a broad industry pivot toward precision immunology and differentiated mechanisms.
The full "Dermatological Drugs 2025 Market" report, is available at: https://www.snsresearch.com/dermatological-drugs-market.html
The report is designed for pharmaceutical executives, strategy and business development teams, investors, and policymakers requiring high-fidelity market intelligence to support decision-making in dermatology.
An accompanying Excel data suite provides all underlying quantitative forecasts and a 2025 clinical pipeline dataset, enabling direct integration into internal models and strategy workflows.
About SNS Research Group LLC
SNS Research Group LLC is a B2B healthcare and pharmaceutical intelligence firm delivering high-signal market reports, clinical pipeline datasets, and executive-grade analysis across specialty therapeutics. The firm focuses on markets where biology, competition, and commercial strategy intersect.
Contact:
SNS Research Group
www.snsresearch.com
[email protected]